JUNSHI BIO(01877) recorded a net loss attributable to equity holders of 596 million RMB in the first three quarters, decreasing by 35.7% year-on-year.

JUNSHI BIO (01877) announces that in the first three quarters of 2025, the operating income was 1.806 billion RMB, a year-on-year increase of 42.06%; the net loss attributable to the shareholders of the listed company was 596 million RMB, a year-on-year decrease of 35.7%; basic loss per share was 0.60 RMB. The increase in the company's operating income during the period was mainly due to the growth in sales revenue of commercialized drugs. Among them, the core product, Teriprituzumab pegol injection (trade names: Tuyi/LOQTORZI, product code: JS001), realized sales revenue of approximately 1.495 billion RMB in the domestic market, a year-on-year increase of approximately 40%. At the same time, the company continued to implement the "improve quality, increase efficiency, and return to profit" action plan, strengthening cost control and resource focus, which significantly narrowed the loss compared to the same period last year. As of the end of the reporting period, the company's total balance of cash and trading financial assets was 3.27 billion RMB, with sufficient reserves.